Latest news with #InternationalConferenceonAlzheimer'sandParkinson'sDiseasesandRelatedNeurologicalDisorders
Yahoo
07-04-2025
- Health
- Yahoo
Data Showcasing ALZpath's Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer's Disease Research and Diagnosis
Findings from Studies on Blood Tests Utilizing the ALZpath pTau217 Antibody – Integral to Many Advanced Assays for Research and Clinical Use - Featured in Seven Oral Presentations and Two Posters CARLSBAD, Calif., April 1, 2025 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer's disease and related dementias, announced the inclusion of data from evaluation of blood testing platforms utilizing its proprietary pTau217 antibody in several high-impact presentations at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™). The data is based on recent studies conducted by industry leaders, including Beckman Coulter Diagnostics, Bio-Techne, and Neurocode, and will be presented in seven symposia, seven oral presentations, and two poster presentations. Alzheimer's disease and related dementias are expected to impact nearly 153 million people globally by 2050. With the increase of cases and emergence of disease-modifying therapies, there is a greater and more urgent need for widespread, rapid, and accessible diagnostic testing. ALZpath's proprietary pTau217 antibody enables highly sensitive and accurate blood-based detection of phosphorylated tau at position 217 (pTau217), a key Alzheimer's disease biomarker, supporting early-stage diagnosis well before symptoms appear. In addition, these blood tests can enable early patient identification, treatment qualification, and response monitoring, while building robust evidence to validate new therapies. Assays incorporating the ALZpath pTau217 biomarker are in development for clinical (IVD) use, including distinct tests with breakthrough device designation from the FDA being advanced by Beckman Coulter Diagnostics and Roche. Other assays containing the ALZpath antibody are already in widespread use in research settings on testing platforms from Alamar Biosciences, Bio-Techne, and Quanterix, as well as in world-class laboratories such as Neurocode. Broadened availability of advanced blood-based assays utilizing ALZpath pTau217 antibody in research and clinical settings may significantly enhance Alzheimer's disease diagnosis and treatment by improving access to accurate and early detection and interventions, enabling risk stratification and monitoring of disease progression, and reducing reliance on other more invasive and costly tests. "This data highlights the importance of ALZpath's pTau217 antibody in transforming Alzheimer's disease diagnosis and treatment, making early detection more accessible as demand continues to rise," said Mike Banville, CEO of ALZpath. "These studies further validate that researchers and clinicians equipped with tests that include our antibody will be better equipped to identify Alzheimer's disease before symptoms appear and the disease has progressed significantly, leading to more timely interventions and improved patient outcomes." ALZpath's pTau217 antibody will be highlighted in seven symposia, seven oral presentations and two poster presentations. These include: Performance of the Beckman Coulter prototype plasma pTau217 and pTau217/aβ42 ratio assays in a cohort of individuals with cognitive impairment Presenter: Paul Wynveen, Senior Staff Scientist in the Clinical Chemistry / Immunoassay Research and Development Department, Beckman Coulter Diagnostics A comprehensive analytical evaluation and diagnostic accuracy study of the ALZpath ptau217 plasma immunoassay in two clinical diagnostic laboratories as a diagnostic test Presenter: Anna Mammel, Neurology Lab Director, Neurocode Leveraging Multiple Canadian Cohorts For Alzheimer's Disease Plasma Biomarker Studies Presenter: Jennifer Cooper, University of British Columbia Risk stratification for amyloid β positivity based on plasma p-tau217 demonstrated diagnostic and prognostic utilities Presenter: Joyce R. Chong, Research Fellow, National University Singapore A Comprehensive Head-to-Head Clinical And Analytical Validation of Two Novel Plasma pTau217 ImmunoAssays in a Clinical Diagnostic Laboratory Presenter: Anna Mammel, Neurology Lab Director, Neurocode Investigation of Plasma Biomarkers for The Detection of Autopsy Confirmed Copathologies in Alzheimer's Disease Presenter: Jennifer Cooper, University of British Columbia The following presentations will be on demand: The Prognostic Value of Plasma pTau217 For Symptom Progression in Older Primary Care Patients- A Real-World Study Presenter: Luca Kleineidam, University of Bonn Precise and Sensitive Quantitation of pTau217 in Plasma and CSF Using an Automated Workflow Presenter: Warren Higgs, Bio-Techne Performance of ALZpath pTau217 in a Clinical Laboratory Presenter: Anna Mammel, Neurology Lab Director, Neurocode "The identification of novel biomarker patterns for detecting specific co-pathologies could significantly improve the accuracy of AD diagnosis and help differentiate between various neurodegenerative diseases, leading to more targeted treatment approaches," said Dr. Cheryl Wellington, Professor at the University of British Columbia. "With high stability across labs and strong diagnostic performance, these findings bring us closer to widespread, accessible early detection—critical for timely intervention and better patient outcomes." About ALZpathALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias. Its ALZpath pTau217 antibody, integral to the most advanced and widely available blood-based tests, is transforming Alzheimer's disease research, diagnosis, treatment and monitoring. To accelerate the development of new medicines and improve patient care for millions, ALZpath democratizes access to its proprietary antibody through licensing agreements with leading global diagnostic and research organizations. These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and impact. ALZpath has been recognized as a Time Magazine Best Invention (2024), Fast Company Most Innovative Company (2025), and Edison Award finalist (2025).To learn more about the company, please visit and follow us on LinkedIn. ALZpath Media ContactNechama View original content: SOURCE ALZpath, Inc. Sign in to access your portfolio
Yahoo
25-03-2025
- Business
- Yahoo
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ('AD/PD™ 2025') taking place online and in Vienna, Austria from April 1 – 5, 2025. AD/PD™ 2025 is a premier event bringing together top international experts to discuss the latest advancements in Alzheimer's and Parkinson's research, clinical trials, and treatments. With over 4,700 participants from 70+ countries and 2,250 abstracts in 2024, it offers a platform for groundbreaking discoveries from the leading experts in the field. Presentation Details: Title: Preliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer's Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01) Session Name: 7540 – Advances in AD Drug Development 02 Session Type: Symposium Presentation Date: Saturday, April 5, 2025, at 5:10 pm – 5:25 pm CEST Room: Hall E Dr. Song's presentation will focus on the three-month cognitive and biomarker results from the Phase 1 cohort of the Phase 1/2a clinical trial for troculeucel NK cell therapy in moderate Alzheimer's disease, as well as new data from the six-month analysis of this cohort. Previously disclosed data for troculeucel in Alzheimer's disease and solid tumors can be found on the Scientific Publications page of the Company's website at News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contacts:Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@
